Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Phosphodiesterase type 5 inhibitors (PDE5-Is) are currently the first-line therapy
for erectile dysfunction (ED), but available studies investigating the comparative
effects of different PDE5-Is are limited.